-
esanum-interview with Prof. Reinhard Büttner, University Hospital Cologne (Germany), on the broad spectrum of pathology and the need of personal exchange. To span the entire bridge from basic pathology – the causal understanding of disease – to applied clinical diagnostic, predictive and evaluative pathology is a key issue of the IAP/ESP Congress 2016 in Cologne.
-
esanum-interview with Prof. Dr. Tibor Tot, Uppsala University (Sweden) on the role of pathology as a busy discipline in connection with breast cancer cases. “In an era of molecular medicine, genetic evaluation and new therapy modalities pathology is a central discipline in all these things.
-
Interview with Prof. Robert Osamura, Sanno Hospital, Tokyo (Japan), on recent developments in cytopathology. With gene-specific targeted cancer therapies the task for the pathologist has increased from the morphologic diagnosis to the genetic information that is needed for a personalized treatment.
-
Interview with Prof. Elisabeth Dequeker, University Leuven (Belgium), on her experiences with external quality assessment (EQA) schemes in pathology. Pathology labs that regularly participate in EQA schemes evidently improve their performance. Furthermore EQA can help to validate and implement new technologies.
-
Interview with Prof. Dietmar Schmidt, Co-President of the Joint IAP/ESP Congress 2016, on the premiere of a joint IAP/ESP congress.
-
Patients with severe Osteoarthritis (OA) benefit from a combination of optimisation of analgetics and a physical training program.
-
The prevalence of gout is increasing, despite good treatment options available. Under diagnosis, late diagnosis, undertreatment and discontinuation of treatment contribute to the rising incidence. These data were presented during an Outcome Science Session at the EULAR Annual Congress 2016 in London.
-
The Emerging EUlar NETwork (EMEUNET) is a network of young clinicians and researchers in Europe with the aim to improve education in rheumatology.
-
A newly developed method of evaluating the impact of different comorbidities in patients with psoriatic Arthritis (PsA) can be used to prospectively identify those PsA patients at greater risk of hospitalisation and premature death.
-
Most patients with non-radiographic axia Spondyloarthritis (SpA) will progress to active SpA, particularly those with elevated C-reactive protein levels.
-
Compared to other biologics, golimumab showed superior persistence rates across different indications and patient groups.
-
One in seven adolescents with juvenile inflammatory arthritis (JIA) experience significant depressive symptoms at diagnosis. Depressive symptoms associate with worse disease and pain at diagnosis with disability over the next three years. These data were presented during a PReS Session at the EULAR Annual Congress 2016 in London.
-
The likelihood of achieving sustained remission in early rheumatoid arthritis (ERA) is significantly lower in patients who smoke and who are obese. Moreover, these potential modifiable lifestyle factors have a high prevalence in patients with ERA.
-
Patients with axial spondyloarthritis who respond early on therapy, show a better persistence long term. Physician's treatment expectations do often not mirror those of the patients.
-
The risk on pre-malignant cervical changes is doubled in women with Systemic Lupus Erythematosus (SLE) compared to the general female population. The highest risks are found in women with SLE who are treated with immunosuppressant drugs. These findings stress the importance for women with SLE to attend cervical screening.
-
A post-hoc analysis of a trial in RA patients shows that biomarkers may help to identify patients at risk for progression and thus enable individualised treatment decisions.
-
Being overweight and radiologic severity of knee osteoarthritis were associated with a lack of response to viscosupplementation in a post hoc analysis of a multicenter, double blind trial.
